Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
Pediatrics and Neonatology|May 22, 2026
Novel susceptible human leukocyte antigens allele in juvenile dermatomyositis: A study in Japanese patientsYuichi Yamasaki, Tomo Nozawa, Shouichirou Kusunoki, et al.
Modern Rheumatology|November 21, 2013
Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patientsTakao Koike, Masayoshi Harigai, Naoki Ishiguro, et al.
The Journal of Rheumatology|November 5, 2013
Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in JapanTakao Koike, Masayoshi Harigai, Shigeko Inokuma, et al.
Modern Rheumatology|November 18, 2022
Long-term efficacy and safety of canakinumab in the treatment of systemic juvenile idiopathic arthritis in Japanese patients: Results from an open-label Phase III studyNaomi Iwata, Kenichi Nishimura, Ryoki Hara, et al.
Modern Rheumatology|June 20, 2020
Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patientsKenichi Nishimura, Ryoki Hara, Hiroaki Umebayashi, et al.
Modern Rheumatology|February 15, 2008
A case of planned pregnancy with an interruption in infliximab administration in a 27-year-old female patient with rheumatoid-factor-positive polyarthritis juvenile idiopathic arthritis which improved after restarting infliximab and methotrexateYasuhito Nerome, Hiroyuki Imanaka, Yukiko Nonaka, et al.
Modern Rheumatology|March 25, 2015
Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in JapanShinsuke Yasuda, Tatsuya Atsumi, Sanae Shimamura, et al.
Modern Rheumatology|June 14, 2011
Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritisTomoyuki Imagawa, Shumpei Yokota, Masaaki Mori, et al.
Rheumatology and Therapy|October 18, 2016
Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study)Takao Koike, Masayoshi Harigai, Naoki Ishiguro, et al.
The Journal of Rheumatology|March 18, 2014
Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in JapanShumpei Yokota, Tomoyuki Imagawa, Masaaki Mori, et al.
Pageof 9